Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia

Acute myeloid leukemia (AML) patients aged ≥60 years tolerate standard induction chemotherapy poorly. Therapy with azacitidine at a dose of 75 mg/m(2)/day for 7 days appears to be better tolerated, and is approved by the Food and Drug Administration (FDA) for the treatment of elderly AML patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadashiv, Santhosh K, Hilton, Christie, Khan, Cyrus, Rossetti, James M, Benjamin, Heather L, Fazal, Salman, Sahovic, Entezam, Shadduck, Richard K, Lister, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298384/
https://www.ncbi.nlm.nih.gov/pubmed/25132519
http://dx.doi.org/10.1002/cam4.321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298384/
https://www.ncbi.nlm.nih.gov/pubmed/25132519
http://dx.doi.org/10.1002/cam4.321

Ejemplares similares